DBV技术公司凭借强劲对比数据，进一步巩固花生过敏贴片VITESSE试验结果

关键事实

1Results showed 83% of children treated with the VIASKIN Peanut Patch increased their eliciting dose compared to 48% in the placebo group.

2Approximately 60% of treated children increased their eliciting dose by at least two doses by month 12.

3The VITESSE study is the largest food allergy immunotherapy trial to date, targeting children aged 4 to 7 years.

DBV技术公司在费城的一次口头报告中公布了其VIASKIN花生贴片的详细III期VITESSE试验数据，进一步增强了其临床概况。研究结果显示，83%的治疗儿童增加了其诱发剂量，显著优于安慰剂组的48%。值得注意的是，60%的治疗受试者实现了两级剂量增加，而安慰剂组仅为23%。该贴片还显示出保护作用，仅有6.4%的治疗受试者出现剂量减少，而安慰剂组为24%。作为迄今为止最大的食物过敏免疫疗法试验，这些结果巩固了4至7岁儿童的监管提交之路。该公司在泛欧交易所巴黎（DBV）和纳斯达克（DBVT）两地上市，目前已为潜在的商业化和未来显著的收入增长做好了充分准备。

免费注册以访问此内容

创建免费账户

版本历史

版本 125 days ago

变更内容: The story was updated with precise comparative data against the placebo group, highlighting the treatment's ability to prevent allergy worsening, and adding details about the presentation location and the company's dual listing status.

来源: